Market closedNon-fractional

Fulcrum Therapeutics/FULC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Ticker

FULC

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Cambridge, United States

Employees

76

FULC Metrics

BasicAdvanced
$383M
Market cap
-
P/E ratio
-$1.61
EPS
2.33
Beta
-
Dividend rate
$383M
2.33
20.381
20.048
3.795
4.746
-25.41%
-39.00%
151.609
1.8
1.8
-4.114
-37.95%
-26.46%
-42.00%
-13.90%

What the Analysts think about FULC

Analyst Ratings

Majority rating from 9 analysts.
Buy

FULC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$27M
8.50%
Profit margin
0.00%
-100.00%

FULC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1.71%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.39
-$0.40
-$0.43
-
Expected
-$0.44
-$0.44
-$0.43
-$0.44
-$0.01
Surprise
-14.52%
-10.34%
-6.04%
-1.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fulcrum Therapeutics stock?

Fulcrum Therapeutics (FULC) has a market cap of $383M as of July 06, 2024.

What is the P/E ratio for Fulcrum Therapeutics stock?

The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of July 06, 2024.

Does Fulcrum Therapeutics stock pay dividends?

No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Fulcrum Therapeutics dividend payment date?

Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.

What is the beta indicator for Fulcrum Therapeutics?

Fulcrum Therapeutics (FULC) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Fulcrum Therapeutics stock

Buy or sell Fulcrum Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing